MX369414B - Peptido. - Google Patents

Peptido.

Info

Publication number
MX369414B
MX369414B MX2015009085A MX2015009085A MX369414B MX 369414 B MX369414 B MX 369414B MX 2015009085 A MX2015009085 A MX 2015009085A MX 2015009085 A MX2015009085 A MX 2015009085A MX 369414 B MX369414 B MX 369414B
Authority
MX
Mexico
Prior art keywords
peptide
apitope
mog
myelin oligodendrocyte
oligodendrocyte glycoprotein
Prior art date
Application number
MX2015009085A
Other languages
English (en)
Other versions
MX2015009085A (es
Inventor
David Wraith
Original Assignee
Apitope Tech Bristol Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apitope Tech Bristol Limited filed Critical Apitope Tech Bristol Limited
Publication of MX2015009085A publication Critical patent/MX2015009085A/es
Publication of MX369414B publication Critical patent/MX369414B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Epidemiology (AREA)

Abstract

La presente invención se refiere a un péptido que es capaz de unirse a una molécula del MHC in vitro y de ser presentado a una célula T sin procesamiento del antígeno, en donde dicho péptido se selecciona de los siguientes péptidos de la glucoproteína de oligodendrocitos de la mielina (MOG), MOG 41-55 (SEQ ID NO: 1), 43-57 (SEQ ID NO: 2) , 44-58 (SEQ ID NO:3) y 45-59 (SEQ ID NO: 4), para usarse en el tratamiento y/o prevención de una enfermedad desmielinizante al unirse al MHC clase II en células que presenta antígeno (APCs) e inducir anergia y tolerancia de células T.
MX2015009085A 2013-01-15 2014-01-13 Peptido. MX369414B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1300684.6A GB201300684D0 (en) 2013-01-15 2013-01-15 Peptide
PCT/IB2014/058233 WO2014111840A2 (en) 2013-01-15 2014-01-13 Peptide

Publications (2)

Publication Number Publication Date
MX2015009085A MX2015009085A (es) 2016-02-16
MX369414B true MX369414B (es) 2019-11-07

Family

ID=47757995

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015009085A MX369414B (es) 2013-01-15 2014-01-13 Peptido.

Country Status (16)

Country Link
US (2) US9862751B2 (es)
EP (1) EP2945966B1 (es)
JP (1) JP6347065B2 (es)
KR (1) KR102169902B1 (es)
CN (1) CN105121463B (es)
AU (1) AU2014206592B2 (es)
BR (1) BR112015016780A2 (es)
CA (1) CA2897655C (es)
GB (1) GB201300684D0 (es)
HK (1) HK1211596A1 (es)
IL (1) IL239871B (es)
MX (1) MX369414B (es)
RU (1) RU2675479C2 (es)
SG (1) SG11201505526TA (es)
WO (1) WO2014111840A2 (es)
ZA (1) ZA201504987B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
CN106986930B (zh) * 2017-04-14 2021-06-11 广东省生物资源应用研究所 一种诱导食蟹猴实验性自身免疫性脑脊髓炎动物模型的蛋白和应用
JP7419229B2 (ja) * 2017-08-14 2024-01-22 百明信康生物技術（浙江）有限公司 方法
GB201909774D0 (en) 2019-07-08 2019-08-21 Apitope Tech Bristol Limited Method

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995006727A2 (en) 1993-09-03 1995-03-09 Immulogic Pharmaceutical Corporation Uses of myelin oligodendrocyte glycoprotein and peptide portions thereof in protocols related to autoimmune disease
WO1995007096A1 (en) 1993-09-06 1995-03-16 La Trobe University Treatment of autoimmune disease
US6251396B1 (en) 1994-11-18 2001-06-26 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
WO1997035879A1 (en) * 1996-03-28 1997-10-02 Immulogic Pharmaceutical Corporation Myelin oligodendrocyte glycoprotein peptides and uses thereof
SE9703287D0 (sv) 1997-09-11 1997-09-11 Astra Ab Peptides
PT1621208E (pt) 1999-03-12 2010-04-07 Univ Leland Stanford Junior Vacinação com adn para tratamento de doença auto-imune
IL132611A0 (en) 1999-10-27 2001-03-19 Yeda Res & Dev Synthetic genes and polypeptides and pharmaceutical compositions comprising them
CA2404340C (en) 2000-03-29 2012-10-16 The Ohio State University Research Foundation Methods of blocking tissue destruction by autoreactive t cells
EP1731912B1 (en) 2000-08-21 2013-09-25 Apitope Technology (Bristol) Limited Peptide selection method
US8231878B2 (en) 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
NZ532199A (en) 2001-10-03 2008-02-29 Harvard College Copolymers for suppression of autoimmune diseases, and methods of use
CA2614171C (en) 2001-10-03 2012-04-24 President And Fellows Of Harvard College Copolymers for suppression of autoimmune diseases, and methods of use
IL146016A0 (en) 2001-10-17 2002-07-25 Yeda Res & Dev Synthetic peptides and dna sequences and compositions comprising them for treatment of multiple sclerosis
ES2388968T3 (es) 2001-11-02 2012-10-22 Giuliani International Limited Inhibidores de Smad7 para el tratamiento de enfermedades del SNC
AU2003258090B2 (en) 2002-08-08 2010-07-22 Baylor College Of Medicine Isolation and identification of T cells
EP2500438A3 (en) 2002-09-25 2012-11-28 Genentech, Inc. Novel compositions and methods for the treatment of psoriasis
EP1625148B1 (en) 2003-05-21 2012-09-26 Biotech Tools S.A. Peptide complex
AU2011202900B2 (en) 2003-09-05 2012-08-02 Oregon Health & Science University Monomeric recombinant MHC molecules useful for manipulation of antigen-specific T cells
AU2004288157B2 (en) 2003-09-05 2011-03-17 Oregon Health & Science University Monomeric recombinant MHC molecules useful for manipulation of antigen-specific T cells
EP1827108B1 (en) 2004-11-29 2015-04-08 Yeda Research And Development Co., Ltd. Induction of neurogenesis and stem cell therapy in combination with copolymer 1
ES2389849T3 (es) 2005-03-14 2012-11-02 Yeda Research And Development Co., Ltd. Ccomposiciones de péptidos HSP60 y antígenos víricos para vacunación y diagnóstico
IL185932A (en) 2005-03-14 2014-02-27 Yeda Res & Dev Viral antigens, conjugates and preparations containing them, for vaccination and diagnosis
AU2012201067A1 (en) 2005-03-14 2012-03-15 B.G. Negev Technologies And Applications Ltd. Compositions of HSP60 peptides and viral antigens for vaccination and diagnosis
US8202835B2 (en) 2005-06-17 2012-06-19 Yitzchak Hillman Disease treatment via antimicrobial peptides or their inhibitors
CN101267834B (zh) 2005-09-28 2013-06-05 赛托斯生物技术公司 白介素-1偶联物及其用途
WO2007055378A1 (ja) 2005-11-14 2007-05-18 Cell Signals Inc. 調節性ｔ細胞の機能異常に基づく疾患の治療方法及び予防方法
US7803364B2 (en) 2005-11-17 2010-09-28 The Cleveland Clinic Foundation Multipotent neural stem cells
WO2007061805A2 (en) 2005-11-17 2007-05-31 The Cleveland Clinic Foundation Multipotent neural stem cells
EP1991259B1 (en) 2006-02-15 2012-10-10 Ramot at Tel-Aviv University Ltd. Viral display vehicles for treating multiple sclerosis
US20080317710A1 (en) 2006-02-22 2008-12-25 University Of Zurich Methods For Treating Autoimmune or Demyelinating Diseases
DK2016414T3 (en) 2006-05-05 2015-12-07 Opexa Therapeutics T-cell vaccine
AU2012202713B2 (en) 2006-05-31 2015-04-09 Lpath, Inc. Immune-derived moieties reactive against lysophosphatidic acid
AU2012202776A1 (en) 2006-05-31 2012-05-31 Lpath, Inc. Novel Bioactive Lipid Derivatives, Immune-derived Moieties Reactive Thereto, and Methods of Making and Using Same
WO2007149982A2 (en) 2006-06-22 2007-12-27 The Brigham And Women's Hospital, Inc. Diagnosis of autoimmune disease
US7832920B2 (en) 2006-10-25 2010-11-16 Revalesio Corporation Mixing device for creating an output mixture by mixing a first material and a second material
US8188218B2 (en) 2006-10-27 2012-05-29 University Of Kansas Bi-functional peptides for multiple sclerosis treatment and diagnosis
RU2460541C2 (ru) 2006-10-27 2012-09-10 Лпат, Инк. Композиции и способы связывания сфингозин-1-фосфата
ES2456963T3 (es) 2007-06-04 2014-04-24 Rappaport Family Institute For Research In The Medical Sciences Agentes para el tratamiento de enfermedades inflamatorias y métodos para usar los mismos
EP2050814A1 (en) 2007-10-17 2009-04-22 Txcell Compositions for treating multiple sclerosis
US20090227018A1 (en) 2007-10-25 2009-09-10 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
MX2010004698A (es) * 2007-10-31 2010-05-13 Apitope Technology Bristol Ltd Composicion.
US20110111395A1 (en) 2008-02-14 2011-05-12 Jean-Marie Saint-Remy Cd4+cells with cytolytic properties
US20110195049A1 (en) 2008-10-13 2011-08-11 Biovista, Inc. Compositions and methods for treating multiple sclerosis
JP5688370B2 (ja) 2008-10-22 2015-03-25 リバルシオ コーポレイション 胸腺間質性リンパ球新生因子（ｔｓｌｐ）媒介状態を治療するための組成物および方法
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
WO2010055510A2 (en) 2008-11-12 2010-05-20 Yeda Research And Development Co. Ltd. Diagnosis of multiple sclerosis
EP2233502A1 (en) 2009-03-27 2010-09-29 Deutsches Rheuma-Forschungszentrum Berlin Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them
CA2758738A1 (en) 2009-04-27 2010-11-04 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
US8703711B2 (en) 2009-06-09 2014-04-22 Val-Chum, Limited Partnership Ninjurin-1 modulation and uses thereof
US8293468B2 (en) 2009-06-10 2012-10-23 Centre Hospitalier De L'université De Montréal MCAM modulation and uses thereof
IN2012DN02753A (es) 2009-08-31 2015-09-18 Amplimmune Inc
KR102223464B1 (ko) 2009-12-09 2021-03-05 미쓰비시 타나베 파마 코퍼레이션 Ｔ 세포 활성화 저해제, 이것을 함유하는 의약 조성물 및 ｔ 세포 활성화 저해 물질의 스크리닝 방법
US20110189178A1 (en) 2010-02-04 2011-08-04 Xencor, Inc. Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
WO2011097527A2 (en) 2010-02-04 2011-08-11 Xencor, Inc. Immunoprotection of therapeutic moieties using enhanced fc regions
PL217128B1 (pl) 2010-08-02 2014-06-30 Inst Biochemii I Biofizyki Polskiej Akademii Nauk Syntetyczne geny kodujące fragmenty peptydowe naturalnych białek mielinowych przeznaczone do wywoływania efektu tolerancji pokarmowej, fragmenty DNA zawierające te geny, sposób otrzymywania tych peptydów w układzie mikrobiologicznym (bakteryjnym) oraz ich zastosowanie medyczne
EP2600885A2 (en) 2010-08-04 2013-06-12 Ramot at Tel Aviv University, Ltd. Methods of treating autoimmune diseases of the central nervous system (cns) and neurodegenerative diseases
US10131875B2 (en) 2010-08-04 2018-11-20 Duke University Regulatory B cells and their uses
KR20130091759A (ko) 2010-08-12 2013-08-19 레발레시오 코퍼레이션 타우병증의 치료를 위한 조성물 및 방법
CN103221424A (zh) 2010-09-03 2013-07-24 俄勒冈健康科学大学 具有共价结合肽的重组t细胞受体配体
US20130236473A1 (en) 2010-09-16 2013-09-12 Osaka University Therapeutic agents and prophylactic agents for symptoms accompanying autoimmune diseases, inflammatory diseases, allergy diseases and organ transplants
CN103200959A (zh) 2010-09-27 2013-07-10 中国农业大学 预防和治疗自身免疫性疾病的联合抗原和dna疫苗
WO2012045324A1 (en) 2010-10-07 2012-04-12 Mediagnost Gesellschaft Fur Forschung Und Herstellung Von Diagnostika Gmbh Method for detecting a parkinson's disease and test system
US20140170168A1 (en) 2010-10-26 2014-06-19 Yoram Reiter Antibodies which bind soluble t-cell receptor ligands
AR093183A1 (es) 2010-12-31 2015-05-27 Anthrogenesis Corp Aumento de la potencia de celulas madre de placenta usando moleculas de arn moduladoras
EP2667888A4 (en) 2011-01-28 2015-11-11 Univ Oregon Health & Science LIGMPHES OF RECOMBINANT T LYMPHOCYTES AND ANTIBODIES BINDING TO LYMPHOCYTES B FOR THE TREATMENT OF AUTOIMMUNE DISEASES
US8685404B2 (en) * 2011-01-31 2014-04-01 Oregon Health & Science University Recombinant T-cell receptor ligand for the treatment of cognitive and neuropsychiatric impairment induced by substance addiction
RS58114B1 (sr) 2011-03-01 2019-02-28 Pharnext Terapija neuroloških poremećaja kombinacijom baklofena i akamprosata
JP5878447B2 (ja) 2012-09-12 2016-03-08 富士フイルム株式会社 ベースメイク化粧料
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide

Also Published As

Publication number Publication date
BR112015016780A2 (pt) 2017-08-15
US20180086802A1 (en) 2018-03-29
CN105121463A (zh) 2015-12-02
SG11201505526TA (en) 2015-08-28
RU2015134356A (ru) 2017-02-22
WO2014111840A3 (en) 2014-10-30
CA2897655C (en) 2023-04-04
US20150353616A1 (en) 2015-12-10
GB201300684D0 (en) 2013-02-27
IL239871A0 (en) 2015-08-31
US9862751B2 (en) 2018-01-09
IL239871B (en) 2018-12-31
JP6347065B2 (ja) 2018-06-27
RU2675479C2 (ru) 2018-12-19
KR20150105365A (ko) 2015-09-16
WO2014111840A2 (en) 2014-07-24
CN105121463B (zh) 2020-11-27
ZA201504987B (en) 2017-11-29
EP2945966B1 (en) 2019-07-03
AU2014206592A1 (en) 2015-07-23
EP2945966A2 (en) 2015-11-25
CA2897655A1 (en) 2014-07-24
KR102169902B1 (ko) 2020-10-26
US10377800B2 (en) 2019-08-13
AU2014206592B2 (en) 2018-01-04
HK1211596A1 (en) 2016-05-27
JP2016505008A (ja) 2016-02-18
MX2015009085A (es) 2016-02-16

Similar Documents

Publication Publication Date Title
PH12018502429A1 (en) Antibody molecules for cancer treatment
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
MX2018015853A (es) Anticuerpos multiespecificos frente a los grupos de diferenciacion 40 y 137 (cd40 y cd137).
CY1117214T1 (el) Συνθεση για ελεγχομενη διεγερση των ωοθηκων
TW201613962A (en) Fabs-in-tandem immunoglobulin and uses thereof
EA201590388A1 (ru) Способы лечения таупатии
MX342675B (es) Formulaciones estables para inyeccion parenteral de farmacos de peptido.
NZ707086A (en) Anti-cd40 antibodies and methods of use
MX359449B (es) Conjugados de anticuerpo fármaco anti-cd70.
NZ631701A (en) Apoptosis-including agents for the treatment of cancer and immune and autoimmune diseases
NZ715201A (en) Afucosylated anti-fgfr2iiib antibodies
MX2017001946A (es) Conjugados de farmacos con anticuerpos anti-cdh6.
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
MX2018006249A (es) Nuevos anticuerpos anti-emr2 y metodos de uso.
MX2012013875A (es) Anticuerpos de union sparc en sangre periferica y usos de los mismos.
MX2023000204A (es) Variantes de proteinas de union al factor h y metodos de uso de estas.
EA201691020A1 (ru) Способы лечения и предотвращения вызываемой аллогенными антителами хронической болезни "трансплантат против хозяина"
EA201791225A1 (ru) Композиции и способы применения солабегрона с модифицированным высвобождением при симптомах нижних мочевых путей
MX2016016419A (es) Conjugados y composiciones de texafirina-pt (iv) para su uso para superar la resistencia del platino.
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
MX369414B (es) Peptido.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
AU2012280776B2 (en) Compounds and pharmaceutical combinations for the treatment of neurodegenerative and ischemic brain diseases
MX2018007817A (es) Nuevos anticuerpos anti-mmp16 y metodos para su uso.
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.

Legal Events

Date Code Title Description
FG Grant or registration